Bevacizumab Inhibits Breast Cancer-Induced Osteolysis, Surrounding Soft Tissue Metastasis, and Angiogenesis in Rats as Visualized by VCT and MRI
Authors:
- Heidegard HilbigHHHeidegard Hilbig
- Sönke BartlingSBSönke Bartling
- Fabian KiesslingFabian Kiessling
- Astrid KerstenAKAstrid Kersten
- Annette Schmitt-GräffASAnnette Schmitt-Gräff
- Hans-Ulrich KauczorHKHans-Ulrich Kauczor
- Stefan DelormeStefan Delorme
- Martin R. BergerMBMartin R. Berger
Open Access
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerNew England Journal of Medicine, 2007
- Advances in optical imaging and novel model systems for cancer metastasis researchClinical & Experimental Metastasis, 2007
- Design of Clinical Trials of Radiation Combined with Antiangiogenic TherapyThe Oncologist, 2007
- Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluationBritish Journal of Cancer, 2006
- The vascular endothelial growth factor receptor (VEGFR‐1) supports growth and survival of human breast carcinomaInternational Journal of Cancer, 2006
- Rat Models of Bone MetastasesClinical & Experimental Metastasis, 2005
- Characterization of a rat model with site‐specific bone metastasis induced by MDA‐MB‐231 breast cancer cells and its application to the effects of an antibody against bone sialoproteinInternational Journal of Cancer, 2005
- Optical Imaging of Cancer Metastasis to Bone MarrowThe American Journal of Pathology, 2002
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Vascular Endothelial Growth Factor Can Substitute for Macrophage Colony-Stimulating Factor in the Support of Osteoclastic Bone ResorptionJournal of Experimental Medicine, 1999